MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR
Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the s...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; spa |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Ali KESHAVARZ-SHOKRI Alexander Russell ABELA Pramod Virupax JOSHI Paul Jhon KRENITSKY Haripada KHATUYA Raymond Stanley GROSS Timothy ALCACIO Jason MCCARTNEY Robert M. HUGHES Jinglan ZHOU Jeremy J. CLEMENS Fabrice Jean Denis PIERRE David Andrew SIESEL Muna SHRESTHA Mark Thomas MILLER Peter Diedierik Jan GROOTENHUIS Ping KANG Clara Kuang-ju HSIA Minson BAEK Andreas P. TERMIN Thomas CLEVELAND Fredrick F. VAN GOOR Sara Sabina HADIDA RUAH Corey ANDERSON Johnny UY Lori Ann FERRIS Anton GULEVICH Tomothy John YOUNG Yi SHI Paul Timothy ANGELL Prasuna PARASELLI Kathy STAVROPOULOS |
| description | Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Se describen compuestos de Fórmula (I): (ver fórmulas) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_MX2019006637A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>MX2019006637A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_MX2019006637A3</originalsourceid><addsrcrecordid>eNqNjrEKwkAQRNNYiPoPi3WEaECx3Fw25jB7F-42oFUQOStRQX_Gv_VEsbaa5r2ZGSZPtmXXoFgHtgK196IVVLpw1msP4tB4Ji5iEihryk4JGkXgaPPRUmhrdIyKuqhiEyluoyzaGp8Ck9S29O9ycYTCZCQFNCW0ziryHqo4zbjVZgNSE_z-jJPB6XC-h8k3R8m0IlH1LNyufbjfDsdwCY-ed4tsvs6y5TJfYf4X9AKLTkQI</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR</title><source>esp@cenet</source><creator>Ali KESHAVARZ-SHOKRI ; Alexander Russell ABELA ; Pramod Virupax JOSHI ; Paul Jhon KRENITSKY ; Haripada KHATUYA ; Raymond Stanley GROSS ; Timothy ALCACIO ; Jason MCCARTNEY ; Robert M. HUGHES ; Jinglan ZHOU ; Jeremy J. CLEMENS ; Fabrice Jean Denis PIERRE ; David Andrew SIESEL ; Muna SHRESTHA ; Mark Thomas MILLER ; Peter Diedierik Jan GROOTENHUIS ; Ping KANG ; Clara Kuang-ju HSIA ; Minson BAEK ; Andreas P. TERMIN ; Thomas CLEVELAND ; Fredrick F. VAN GOOR ; Sara Sabina HADIDA RUAH ; Corey ANDERSON ; Johnny UY ; Lori Ann FERRIS ; Anton GULEVICH ; Tomothy John YOUNG ; Yi SHI ; Paul Timothy ANGELL ; Prasuna PARASELLI ; Kathy STAVROPOULOS</creator><creatorcontrib>Ali KESHAVARZ-SHOKRI ; Alexander Russell ABELA ; Pramod Virupax JOSHI ; Paul Jhon KRENITSKY ; Haripada KHATUYA ; Raymond Stanley GROSS ; Timothy ALCACIO ; Jason MCCARTNEY ; Robert M. HUGHES ; Jinglan ZHOU ; Jeremy J. CLEMENS ; Fabrice Jean Denis PIERRE ; David Andrew SIESEL ; Muna SHRESTHA ; Mark Thomas MILLER ; Peter Diedierik Jan GROOTENHUIS ; Ping KANG ; Clara Kuang-ju HSIA ; Minson BAEK ; Andreas P. TERMIN ; Thomas CLEVELAND ; Fredrick F. VAN GOOR ; Sara Sabina HADIDA RUAH ; Corey ANDERSON ; Johnny UY ; Lori Ann FERRIS ; Anton GULEVICH ; Tomothy John YOUNG ; Yi SHI ; Paul Timothy ANGELL ; Prasuna PARASELLI ; Kathy STAVROPOULOS</creatorcontrib><description>Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Se describen compuestos de Fórmula (I): (ver fórmulas) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.</description><language>eng ; spa</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2019</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190821&DB=EPODOC&CC=MX&NR=2019006637A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190821&DB=EPODOC&CC=MX&NR=2019006637A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Ali KESHAVARZ-SHOKRI</creatorcontrib><creatorcontrib>Alexander Russell ABELA</creatorcontrib><creatorcontrib>Pramod Virupax JOSHI</creatorcontrib><creatorcontrib>Paul Jhon KRENITSKY</creatorcontrib><creatorcontrib>Haripada KHATUYA</creatorcontrib><creatorcontrib>Raymond Stanley GROSS</creatorcontrib><creatorcontrib>Timothy ALCACIO</creatorcontrib><creatorcontrib>Jason MCCARTNEY</creatorcontrib><creatorcontrib>Robert M. HUGHES</creatorcontrib><creatorcontrib>Jinglan ZHOU</creatorcontrib><creatorcontrib>Jeremy J. CLEMENS</creatorcontrib><creatorcontrib>Fabrice Jean Denis PIERRE</creatorcontrib><creatorcontrib>David Andrew SIESEL</creatorcontrib><creatorcontrib>Muna SHRESTHA</creatorcontrib><creatorcontrib>Mark Thomas MILLER</creatorcontrib><creatorcontrib>Peter Diedierik Jan GROOTENHUIS</creatorcontrib><creatorcontrib>Ping KANG</creatorcontrib><creatorcontrib>Clara Kuang-ju HSIA</creatorcontrib><creatorcontrib>Minson BAEK</creatorcontrib><creatorcontrib>Andreas P. TERMIN</creatorcontrib><creatorcontrib>Thomas CLEVELAND</creatorcontrib><creatorcontrib>Fredrick F. VAN GOOR</creatorcontrib><creatorcontrib>Sara Sabina HADIDA RUAH</creatorcontrib><creatorcontrib>Corey ANDERSON</creatorcontrib><creatorcontrib>Johnny UY</creatorcontrib><creatorcontrib>Lori Ann FERRIS</creatorcontrib><creatorcontrib>Anton GULEVICH</creatorcontrib><creatorcontrib>Tomothy John YOUNG</creatorcontrib><creatorcontrib>Yi SHI</creatorcontrib><creatorcontrib>Paul Timothy ANGELL</creatorcontrib><creatorcontrib>Prasuna PARASELLI</creatorcontrib><creatorcontrib>Kathy STAVROPOULOS</creatorcontrib><title>MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR</title><description>Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Se describen compuestos de Fórmula (I): (ver fórmulas) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2019</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjrEKwkAQRNNYiPoPi3WEaECx3Fw25jB7F-42oFUQOStRQX_Gv_VEsbaa5r2ZGSZPtmXXoFgHtgK196IVVLpw1msP4tB4Ji5iEihryk4JGkXgaPPRUmhrdIyKuqhiEyluoyzaGp8Ck9S29O9ycYTCZCQFNCW0ziryHqo4zbjVZgNSE_z-jJPB6XC-h8k3R8m0IlH1LNyufbjfDsdwCY-ed4tsvs6y5TJfYf4X9AKLTkQI</recordid><startdate>20190821</startdate><enddate>20190821</enddate><creator>Ali KESHAVARZ-SHOKRI</creator><creator>Alexander Russell ABELA</creator><creator>Pramod Virupax JOSHI</creator><creator>Paul Jhon KRENITSKY</creator><creator>Haripada KHATUYA</creator><creator>Raymond Stanley GROSS</creator><creator>Timothy ALCACIO</creator><creator>Jason MCCARTNEY</creator><creator>Robert M. HUGHES</creator><creator>Jinglan ZHOU</creator><creator>Jeremy J. CLEMENS</creator><creator>Fabrice Jean Denis PIERRE</creator><creator>David Andrew SIESEL</creator><creator>Muna SHRESTHA</creator><creator>Mark Thomas MILLER</creator><creator>Peter Diedierik Jan GROOTENHUIS</creator><creator>Ping KANG</creator><creator>Clara Kuang-ju HSIA</creator><creator>Minson BAEK</creator><creator>Andreas P. TERMIN</creator><creator>Thomas CLEVELAND</creator><creator>Fredrick F. VAN GOOR</creator><creator>Sara Sabina HADIDA RUAH</creator><creator>Corey ANDERSON</creator><creator>Johnny UY</creator><creator>Lori Ann FERRIS</creator><creator>Anton GULEVICH</creator><creator>Tomothy John YOUNG</creator><creator>Yi SHI</creator><creator>Paul Timothy ANGELL</creator><creator>Prasuna PARASELLI</creator><creator>Kathy STAVROPOULOS</creator><scope>EVB</scope></search><sort><creationdate>20190821</creationdate><title>MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR</title><author>Ali KESHAVARZ-SHOKRI ; Alexander Russell ABELA ; Pramod Virupax JOSHI ; Paul Jhon KRENITSKY ; Haripada KHATUYA ; Raymond Stanley GROSS ; Timothy ALCACIO ; Jason MCCARTNEY ; Robert M. HUGHES ; Jinglan ZHOU ; Jeremy J. CLEMENS ; Fabrice Jean Denis PIERRE ; David Andrew SIESEL ; Muna SHRESTHA ; Mark Thomas MILLER ; Peter Diedierik Jan GROOTENHUIS ; Ping KANG ; Clara Kuang-ju HSIA ; Minson BAEK ; Andreas P. TERMIN ; Thomas CLEVELAND ; Fredrick F. VAN GOOR ; Sara Sabina HADIDA RUAH ; Corey ANDERSON ; Johnny UY ; Lori Ann FERRIS ; Anton GULEVICH ; Tomothy John YOUNG ; Yi SHI ; Paul Timothy ANGELL ; Prasuna PARASELLI ; Kathy STAVROPOULOS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_MX2019006637A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; spa</language><creationdate>2019</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>Ali KESHAVARZ-SHOKRI</creatorcontrib><creatorcontrib>Alexander Russell ABELA</creatorcontrib><creatorcontrib>Pramod Virupax JOSHI</creatorcontrib><creatorcontrib>Paul Jhon KRENITSKY</creatorcontrib><creatorcontrib>Haripada KHATUYA</creatorcontrib><creatorcontrib>Raymond Stanley GROSS</creatorcontrib><creatorcontrib>Timothy ALCACIO</creatorcontrib><creatorcontrib>Jason MCCARTNEY</creatorcontrib><creatorcontrib>Robert M. HUGHES</creatorcontrib><creatorcontrib>Jinglan ZHOU</creatorcontrib><creatorcontrib>Jeremy J. CLEMENS</creatorcontrib><creatorcontrib>Fabrice Jean Denis PIERRE</creatorcontrib><creatorcontrib>David Andrew SIESEL</creatorcontrib><creatorcontrib>Muna SHRESTHA</creatorcontrib><creatorcontrib>Mark Thomas MILLER</creatorcontrib><creatorcontrib>Peter Diedierik Jan GROOTENHUIS</creatorcontrib><creatorcontrib>Ping KANG</creatorcontrib><creatorcontrib>Clara Kuang-ju HSIA</creatorcontrib><creatorcontrib>Minson BAEK</creatorcontrib><creatorcontrib>Andreas P. TERMIN</creatorcontrib><creatorcontrib>Thomas CLEVELAND</creatorcontrib><creatorcontrib>Fredrick F. VAN GOOR</creatorcontrib><creatorcontrib>Sara Sabina HADIDA RUAH</creatorcontrib><creatorcontrib>Corey ANDERSON</creatorcontrib><creatorcontrib>Johnny UY</creatorcontrib><creatorcontrib>Lori Ann FERRIS</creatorcontrib><creatorcontrib>Anton GULEVICH</creatorcontrib><creatorcontrib>Tomothy John YOUNG</creatorcontrib><creatorcontrib>Yi SHI</creatorcontrib><creatorcontrib>Paul Timothy ANGELL</creatorcontrib><creatorcontrib>Prasuna PARASELLI</creatorcontrib><creatorcontrib>Kathy STAVROPOULOS</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Ali KESHAVARZ-SHOKRI</au><au>Alexander Russell ABELA</au><au>Pramod Virupax JOSHI</au><au>Paul Jhon KRENITSKY</au><au>Haripada KHATUYA</au><au>Raymond Stanley GROSS</au><au>Timothy ALCACIO</au><au>Jason MCCARTNEY</au><au>Robert M. HUGHES</au><au>Jinglan ZHOU</au><au>Jeremy J. CLEMENS</au><au>Fabrice Jean Denis PIERRE</au><au>David Andrew SIESEL</au><au>Muna SHRESTHA</au><au>Mark Thomas MILLER</au><au>Peter Diedierik Jan GROOTENHUIS</au><au>Ping KANG</au><au>Clara Kuang-ju HSIA</au><au>Minson BAEK</au><au>Andreas P. TERMIN</au><au>Thomas CLEVELAND</au><au>Fredrick F. VAN GOOR</au><au>Sara Sabina HADIDA RUAH</au><au>Corey ANDERSON</au><au>Johnny UY</au><au>Lori Ann FERRIS</au><au>Anton GULEVICH</au><au>Tomothy John YOUNG</au><au>Yi SHI</au><au>Paul Timothy ANGELL</au><au>Prasuna PARASELLI</au><au>Kathy STAVROPOULOS</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR</title><date>2019-08-21</date><risdate>2019</risdate><abstract>Compounds of Formula (I) pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Se describen compuestos de Fórmula (I): (ver fórmulas) sales farmacéuticamente aceptables de este, derivados deuterados de cualquiera de los anteriores y metabolitos de cualquiera de los anteriores. También se describen composiciones farmacéuticas que los comprenden, métodos para el tratamiento de la fibrosis quística mediante el uso de estos y métodos para confeccionarlos. Se describen además las formas en estado sólido del Compuesto 1 y sales y solvatos de este.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; spa |
| recordid | cdi_epo_espacenet_MX2019006637A |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | MODULATOR OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR, PHARMACEUTICAL COMPOSITIONS, METHODS OF TREATMENT, AND PROCESS FOR MAKING THE MODULATOR |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T11%3A09%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Ali%20KESHAVARZ-SHOKRI&rft.date=2019-08-21&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EMX2019006637A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |